22,415 Shares in Cabot Corporation $CBT Purchased by Isthmus Partners LLC

Isthmus Partners LLC bought a new position in shares of Cabot Corporation (NYSE:CBTFree Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 22,415 shares of the specialty chemicals company’s stock, valued at approximately $1,486,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Torren Management LLC acquired a new stake in shares of Cabot during the 4th quarter worth approximately $26,000. Smartleaf Asset Management LLC lifted its holdings in Cabot by 598.0% in the third quarter. Smartleaf Asset Management LLC now owns 349 shares of the specialty chemicals company’s stock valued at $27,000 after acquiring an additional 299 shares during the last quarter. Hantz Financial Services Inc. grew its position in Cabot by 227.5% in the third quarter. Hantz Financial Services Inc. now owns 429 shares of the specialty chemicals company’s stock worth $33,000 after acquiring an additional 298 shares during the period. Geneos Wealth Management Inc. grew its position in Cabot by 409.0% in the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after acquiring an additional 364 shares during the period. Finally, Danske Bank A S acquired a new stake in Cabot during the third quarter worth $38,000. 93.18% of the stock is currently owned by institutional investors and hedge funds.

Cabot Trading Down 1.3%

CBT opened at $81.04 on Friday. Cabot Corporation has a 52 week low of $58.33 and a 52 week high of $86.43. The company has a quick ratio of 0.96, a current ratio of 1.45 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $74.88 and a 200-day simple moving average of $70.96. The firm has a market cap of $4.18 billion, a P/E ratio of 15.32, a P/E/G ratio of 10.74 and a beta of 0.78.

Cabot (NYSE:CBTGet Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The specialty chemicals company reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.14. Cabot had a return on equity of 21.33% and a net margin of 7.97%.The firm had revenue of $904.00 million for the quarter, compared to the consensus estimate of $900.31 million. During the same quarter in the previous year, the business earned $1.90 EPS. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. Cabot has set its FY 2026 guidance at 6.000-6.50 EPS. On average, equities analysts expect that Cabot Corporation will post 6.32 earnings per share for the current year.

Cabot Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 29th will be given a dividend of $0.4725 per share. This is a boost from Cabot’s previous quarterly dividend of $0.45. This represents a $1.89 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, May 29th. Cabot’s dividend payout ratio is currently 34.03%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Cabot from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Mizuho raised their price objective on Cabot from $75.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Jefferies Financial Group restated a “buy” rating and issued a $85.00 price objective on shares of Cabot in a report on Wednesday, February 4th. Zacks Research raised shares of Cabot from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 27th. Finally, UBS Group lifted their price target on shares of Cabot from $81.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $80.25.

Get Our Latest Research Report on CBT

Cabot Company Profile

(Free Report)

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

Featured Articles

Want to see what other hedge funds are holding CBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cabot Corporation (NYSE:CBTFree Report).

Institutional Ownership by Quarter for Cabot (NYSE:CBT)

Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.